Tags

Type your tag names separated by a space and hit enter

Clarithromycin (Biaxin) extended-release tablet: a therapeutic review.
Expert Rev Anti Infect Ther. 2003 Jun; 1(1):9-20.ER

Abstract

Clarithromycin (Biaxin) extended-release tablets, an advanced generation macrolide, were recently introduced into the USA for the treatment of acute exacerbations of chronic bronchitis, community-acquired pneumonia and acute maxillary sinusitis. The reformulation is intended to improve both patient compliance and tolerability. The extended-release tablets allow convenient once-daily dosing (1000 mg). The extended-release formulation has been shown to be equivalent to the immediate-release formulation concerning area under the plasma concentration time curve. In comparative clinical trials for acute exacerbations of chronic bronchitis, community-acquired pneumonia and acute maxillary sinusitis, clarithromycin extended-release tablets were equivalent to the immediate-release formulation concerning clinical efficacy and bacterial eradication, with improved gastrointestinal tolerability. Similar efficacy and gastrointestinal tolerability results were demonstrated in a recent comparative study of clarithromycin extended-release formulation and amoxicillin-clavulanate in patients with acute exacerbations of chronic bronchitis. Clarithromycin extended-release 1000 mg daily has also been shown to be equivalent to levofloxacin 500 mg daily for the treatment of community-acquired pneumonia in a recent study. The macrolide class of antimicrobials, including clarithromycin extended-release, continues to be a safe and efficacious choice for the out-patient management of community-acquired bacterial respiratory tract infections.

Authors+Show Affiliations

Pulmonary Associates, 9225 N. Third Street, Suite 200B, Phoenix, Arizona 85020, USA. mgotfried@aol.com.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

15482099

Citation

Gotfried, Mark H.. "Clarithromycin (Biaxin) Extended-release Tablet: a Therapeutic Review." Expert Review of Anti-infective Therapy, vol. 1, no. 1, 2003, pp. 9-20.
Gotfried MH. Clarithromycin (Biaxin) extended-release tablet: a therapeutic review. Expert Rev Anti Infect Ther. 2003;1(1):9-20.
Gotfried, M. H. (2003). Clarithromycin (Biaxin) extended-release tablet: a therapeutic review. Expert Review of Anti-infective Therapy, 1(1), 9-20.
Gotfried MH. Clarithromycin (Biaxin) Extended-release Tablet: a Therapeutic Review. Expert Rev Anti Infect Ther. 2003;1(1):9-20. PubMed PMID: 15482099.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clarithromycin (Biaxin) extended-release tablet: a therapeutic review. A1 - Gotfried,Mark H, PY - 2004/10/16/pubmed PY - 2004/10/29/medline PY - 2004/10/16/entrez SP - 9 EP - 20 JF - Expert review of anti-infective therapy JO - Expert Rev Anti Infect Ther VL - 1 IS - 1 N2 - Clarithromycin (Biaxin) extended-release tablets, an advanced generation macrolide, were recently introduced into the USA for the treatment of acute exacerbations of chronic bronchitis, community-acquired pneumonia and acute maxillary sinusitis. The reformulation is intended to improve both patient compliance and tolerability. The extended-release tablets allow convenient once-daily dosing (1000 mg). The extended-release formulation has been shown to be equivalent to the immediate-release formulation concerning area under the plasma concentration time curve. In comparative clinical trials for acute exacerbations of chronic bronchitis, community-acquired pneumonia and acute maxillary sinusitis, clarithromycin extended-release tablets were equivalent to the immediate-release formulation concerning clinical efficacy and bacterial eradication, with improved gastrointestinal tolerability. Similar efficacy and gastrointestinal tolerability results were demonstrated in a recent comparative study of clarithromycin extended-release formulation and amoxicillin-clavulanate in patients with acute exacerbations of chronic bronchitis. Clarithromycin extended-release 1000 mg daily has also been shown to be equivalent to levofloxacin 500 mg daily for the treatment of community-acquired pneumonia in a recent study. The macrolide class of antimicrobials, including clarithromycin extended-release, continues to be a safe and efficacious choice for the out-patient management of community-acquired bacterial respiratory tract infections. SN - 1478-7210 UR - https://www.unboundmedicine.com/medline/citation/15482099/Clarithromycin__Biaxin__extended_release_tablet:_a_therapeutic_review_ L2 - https://www.tandfonline.com/doi/full/10.1586/14787210.1.1.9 DB - PRIME DP - Unbound Medicine ER -